Abstract:The coronavirus disease 2019 (COVID-19) posed unprecedented challenges to health care systems worldwide, necessitating comprehensive research efforts to gain a better understanding of its diverse clinical presentations and associated complications. Among the numerous consequences of infection with the severe acute respiratory syndrome coronavirus 2, venous thromboembolism stands out as a critical concern, significantly contributing to both the morbidity and mortality of individuals hospitalized with COVID-19.[1] [2] Whole blood viscosity (WBV) serves as a validated measure of the resistance to shear stress encountered during blood flow within the circulatory system. Several studies have directly assessed WBV in COVID-19 patients and consistently reported elevated values when compared with uninfected individuals.[3] [4] Alterations in blood viscosity can influence microcirculation, exacerbate inflammation, and potentiate thrombosis, thereby playing a pivotal role in the pathogenesis of COVID-19-associated thromboembolic complications.[5] In retrospective cohort studies of hospitalized COVID-19 patients, increased high-shear and low-shear blood viscosity were significantly associated with higher in-hospital mortality and poor prognosis.[6] [7] Specifically, a 1 centipoise rise in high-shear viscosity was linked to a 36% increased risk of death ( p < 0.001),[7] and there was a decreased likelihood of being respiratory organ support-free at 21 days, with an odds ratio (OR) of 0.68 ( p < 0.001).[6] The Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC; NCT04372589) and A Multicenter, Adaptive, Randomized Controlled Platform Trial of the Safety and Efficacy of Antithrombotic Strategies in Hospitalized Adults with COVID-19 (ACTIV-4a; NCT04505774) platforms investigated therapeutic strategies to mitigate the thrombotic risk associated with COVID-19.[8] [9] These platforms reported improved survival and clinical outcomes with therapeutic-dose anticoagulation among noncritically ill patients with COVID-19, but not among those with critical illness. In this context, we conducted a post hoc analysis to explore the relationship between WBV and thromboembolic events in hospitalized patients with COVID-19. The study design and primary results of the trial has been previously published.[8] [9] The study received approval from the ethics committee and written or oral informed consent was obtained from all participants or their surrogates. Hospitalized patients with COVID-19 were enrolled in the trial. Exclusion criteria included patients with an imminent risk of death, a high risk of bleeding, those receiving dual antiplatelet therapy, individuals with a separate clinical indication for therapeutic-dose anticoagulation, or a history of heparin-induced cytopenia. Detailed exclusion criteria were published in a previous study.[8] [9] Estimated blood viscosity was calculated using the Walburn–Schneck model, which has been previously validated in a study involving COVID-19 patients.[10] [11] [12] The primary outcome of interest was composite outcome of 90-day mortality, venous thromboembolism events, and arterial thromboembolism events. Based on the calculated high-shear and low-shear blood viscosity values, participants were categorized into high- and low-blood viscosity groups using the median value. We used chi-square tests for categorical variables and t -tests for continuous variables to assess statistical significance between the high- and low-blood viscosity groups. Multivariable logistic regression was then conducted to determine ORs and their corresponding 95% confidence intervals (CIs) for the primary outcomes. Considered covariates were age, sex and oxygen requirement at presentation. All analyses were performed using SAS 9.4. We considered p -values less than 0.05 as statistically significant, and all p -values were evaluated using two-tailed tests. Baseline characteristics of the study population are presented in [Table 1]. Participants with higher blood viscosity were more likely to be male, of White or Hispanic ethnicity, younger in age, and had fewer comorbidities compared with those with lower blood viscosity. [Table 2] shows the associated of blood viscosity and primary outcome. A total of 149 primary composite outcome events were identified with a total event rate of 15.7%. However, COVID-19 patients with higher high-shear blood viscosity did not exhibit significantly different odds of developing the primary composite outcome (OR: 0.72, 95% CI: 0.51–1.02, p = 0.07). Variables High-shear BV lower half High-shear BV upper half p -Value BV range, cP 1.90–2.93 2.94–4.37 Severity status (%) 0.074 Seve -Abstract Truncated-

Altered pulmonary blood volume distribution as a biomarker for predicting outcomes in COVID-19 disease

CT-derived measurements of pulmonary blood volume in small vessels and the need for supplemental oxygen in COVID-19 patients

IP-10 and MCP-1 As Biomarkers Predicting Disease Severity of COVID-19

Combined Clinical and Imaging Features Better Predict the Critical Outcomes of Patients with SARS-COV-2.

Prognostic value of right ventricular dilatation on computed tomography pulmonary angiogram for predicting adverse clinical events in severe COVID-19 pneumonia

Comparison of Different Vascular Biomarkers for Predicting In-Hospital Mortality in Severe SARS-CoV-2 Infection

Pulmonary artery diameter and NT-proBNP in patients with Covid-19: Predicting prognosis and mortality

Combined coagulation and inflammation markers as predictors of venous thrombo-embolism and death in COVID-19

CT-Based Risk Factors for Mortality of Patients with COVID-19 Pneumonia in Wuhan, China: A Retrospective Study

Abstract 15571: Echocardiographic Characteristics and Their Association With Outcome in Hospitalized Covid-19 Patients With Cardiovascular Disease

Endothelial biomarkers (Von willebrand factor, BDCA3, urokinase) as predictors of mortality in COVID-19 patients: cohort study

CT Quantification of COVID-19 Pneumonia at Admission Can Predict Progression to Critical Illness: A Retrospective Multicenter Cohort Study

Parasternal intercostal thickening at hospital admission: a promising indicator for mechanical ventilation risk in subjects with severe COVID-19

Biventricular Longitudinal Strain Predict Mortality in COVID-19 Patients

Risk stratification and prediction of severity of COVID-19 infection in patients with preexisting cardiovascular disease

Progressive changes in pulmonary gas exchange during invasive respiratory support for COVID‐19 associated acute respiratory failure: A retrospective study of the association with 90‐day mortality

Estimated plasma volume status in COVID-19 patients and its relation to comorbidities and clinical outcomes

Whole Blood Viscosity and Thromboembolic Events in Hospitalized Patients with COVID-19: Post hoc Analysis of the ATTACC/ACTIV-4a Trial

Three Different Approaches to Quantify the Burden of Viral Interstitial Pneumonia Using COVID-19 as a Paradigm

The Prognostic Value of Cardiac Biomarkers and Echocardiography in Critical COVID-19

Abstract 11806: CT Measure of Intraparenchymal Vascular Volume in Chronic Obstructive Pulmonary Disease Patients With and Without Pulmonary Hypertension